Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Herbalife exec

This article was originally published in The Tan Sheet

Executive Summary

Richard Goudis, 43, was named Herbalife chief financial officer, Los Angeles-based firm says June 14. Goudis will report directly to CEO Michael Johnson, who took over in April 2003 (1"The Tan Sheet" April 7, 2003, In Brief). Goudis, who brings previous experience as COO of Rexall Sundown and positions at Pratt & Whitney and Sunbeam Corporation, will be responsible for global financial and accounting activities. He replaces Bill Lowe, Sr. VP-finance, who served as CFO during the search...

You may also be interested in...



New Herbalife CEO

Michael Johnson succeeds Francis Tirelli as CEO effective April 14, direct marketer announces. Johnson is a 17-year veteran of Walt Disney Corporation, where he most recently served as president of Walt Disney International. Herbalife was taken private July 31 after acquisition by an investor group led by equity firms Whitney & Co., Golden Gate Capital, Herbalife senior management (1"The Tan Sheet" Aug. 5, 2002, In Brief). Tirelli resigned from CEO post in September to pursue other opportunities...

Alvotech And Cipla Expand Biosimilars Deal For Australia And New Zealand

Cipla has expanded its partnership with Alvotech to cover the commercialization of five biosimilars in Australia and New Zealand, building on an existing alliance covering South Africa and emerging markets.

No Eudamed, No Problem! Latest Guidance Explains Alternatives While Database Is Built

Lack of official explanation about how the exchange of critical information will progress pending the launch of the EU’s medical device database, Eudamed3, has left many confused. New guidance lights the way forward.

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel